他汀和/或依折麦布治疗患者的依从性与治疗强度联合指标与心血管结局的关联
该回顾性队列研究利用英国临床实践研究数据链(2010年1月至2016年2月),纳入29797例新接受他汀和/或依折麦布治疗的患者,分为确诊心血管病(16701例)、无心血管病或慢性肾病的2型糖尿病(12422例)及无心血管病的慢性肾病(674例)三个队列。依从性以覆盖天数比例≥80%定义,治疗强度按指南预期低密度脂蛋白胆固醇降低幅度分为低(<30%)、中(30%至<50%)、高(≥50%)三档,两者相乘形成联合指标。主要复合终点为心血管死亡或心肌梗死、不稳定型心绞痛、缺血性卒中、心力衰竭或血运重建住院。结果显示联合指标每增加10%,风险降低10%(HR 0.90;95%CI 0.86-0.94);与未治疗≥1年者相比,依从且接受高强度方案者风险最低(HR 0.60;95%CI 0.54-0.68),其他两个队列结果相似。
要点
- 在确诊心血管病队列中,接受高强度治疗者长期依从比例更高:第1年84.1%、第6年72.3%,而低强度治疗者为第1年57.4%、第6年48.4%。
- 依从性与治疗强度联合指标每增加10%,主要心血管复合终点风险降低10%(HR 0.90;95%CI 0.86-0.94)。
- 与未治疗≥1年者相比,依从且接受高强度降脂方案的患者风险最低(HR 0.60;95%CI 0.54-0.68)。
- 无心血管病或慢性肾病的2型糖尿病队列及无心血管病的慢性肾病队列结果与确诊心血管病队列相似。
- 依从性以覆盖天数比例≥80%定义,治疗强度按指南预期低密度脂蛋白胆固醇降低幅度分为低(<30%)、中(30%至<50%)、高(≥50%)三档。
适用人群与场景
- 新接受他汀和/或依折麦布治疗、且在随后一年内再次开具他汀和/或依折麦布处方的患者,数据来自英国初级保健。
- 纳入三个队列:确诊心血管病者16701例(平均年龄68.3岁,男性60.6%);无心血管病或慢性肾病的2型糖尿病者12422例(平均年龄59.3岁,男性55.0%);无心血管病的慢性肾病者674例(平均年龄67.3岁,男性47.0%)。
诊断标准与关键阈值
- 依从性以覆盖天数比例评估,覆盖天数比例≥80%定义为依从。
- 治疗强度按指南基于预期低密度脂蛋白胆固醇降低百分比分类:低强度为<30%降低,中强度为30%至<50%降低,高强度为≥50%降低。
- 联合指标为依从性与治疗强度相乘,反映校正依从性后的治疗强度。
研究设计与关键结果
- 研究类型为回顾性队列研究,使用临床实践研究数据链,时间范围为2010年1月至2016年2月,场景为英国初级保健,共纳入29797例新治疗患者。
- 在确诊心血管病队列中,高强度治疗者依从比例第1年为84.1%、第6年为72.3%,低强度治疗者第1年为57.4%、第6年为48.4%。
- 联合指标每增加10%,主要心血管复合终点风险降低10%(HR 0.90;95%CI 0.86-0.94)。
- 与未治疗≥1年者相比,依从且接受高强度方案者风险最低(HR 0.60;95%CI 0.54-0.68)。
- 其他两个队列(无心血管病或慢性肾病的2型糖尿病、无心血管病的慢性肾病)结果与确诊心血管病队列相似。
证据类型、等级与局限
- 证据类型为回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,改善依从性和更多使用强化治疗策略可能大幅改善心血管风险。
- 研究显示,依从且接受高强度降脂治疗的患者心血管风险最低,而不依从且接受低强度治疗的患者风险最高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Both adherence and treatment intensity can alter the effectiveness of lipid-lowering therapy in routine clinical practice.
OBJECTIVE: To evaluate the association of adherence and treatment intensity with cardiovascular outcomes in patients with documented cardiovascular disease (CVD), type 2 diabetes without CVD or chronic kidney disease (CKD), and CKD without CVD.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using the Clinical Practice Research Datalink from January 2010 through February 2016. United Kingdom primary care was the setting. Participants were newly treated patients who received their first statin and/or ezetimibe prescription between January 1, 2010, and December 31, 2013, plus an additional prescription for statins and/or ezetimibe during the following year.
EXPOSURES: Adherence was assessed annually using the proportion of days covered, with adherent defined as a proportion of days covered of 80% or higher. Treatment intensity was classified according to guidelines based on the expected percentage of low-density lipoprotein cholesterol (LDL-C) reduction as low (<30% reduction), moderate (30% to <50% reduction), or high (≥50% reduction). Adherence and treatment intensity were multiplied to create a combined measure, reflecting treatment intensity after accounting for adherence.
MAIN OUTCOMES AND MEASURES: Composite end point of cardiovascular death or hospitalization for myocardial infarction, unstable angina, ischemic stroke, heart failure, or revascularization. Hazard ratios (HRs) were estimated against patients not treated for 1 year or longer.
RESULTS: Among a total of 29 797 newly treated patients, there were 16 701, 12 422, and 674 patients with documented CVD, type 2 diabetes without CVD or CKD, and CKD without CVD, respectively; mean (SD) ages were 68.3 (13.2), 59.3 (12.4), and 67.3 (15.1) years, and male proportions were 60.6%, 55.0%, and 47.0%. In the documented CVD cohort, patients receiving high-intensity therapy were more likely to be adherent over time (84.1% in year 1 and 72.3% in year 6) than patients receiving low-intensity therapy (57.4% in year 1 and 48.4% in year 6). Using a combined measure of adherence and treatment intensity, a graded association was observed with both LDL-C reduction and CVD outcomes: each 10% increase in the combined measure was associated with a 10% lower risk (HR, 0.90; 95% CI, 0.86-0.94). Adherent patients receiving a high-intensity regimen had the lowest risk (HR, 0.60; 95% CI, 0.54-0.68) vs patients untreated for 1 year or longer. Findings in the other 2 cohorts were similar.
CONCLUSIONS AND RELEVANCE: Results of this study demonstrate that the lowest cardiovascular risk was observed among adherent patients receiving high-intensity therapy, and the highest cardiovascular risk was observed among nonadherent patients receiving low-intensity therapy. Strategies that improve adherence and greater use of intensive therapies could substantially improve cardiovascular risk.
参考来源
- Khunti K, Danese MD, Kutikova L, et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open. 2018. PMID: 30646277. doi:10.1001/jamanetworkopen.2018.5554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。